Merck & Co., Inc. (MRK)
$36.29
-0.28 (-0.77%)
| CAPS Rating |
|
|---|---|
| Open | $35.98 |
| Previous Close | $36.57 |
| Daily Range | $35.62 - $36.54 |
| 52-Week Range | $31.25 - $36.96 |
| Market Cap | $76.54B |
| P/E Ratio | 9.53 |
| Dividend (Yield) | 15.00 (5.90%) |
| Volume | 8,970,439 |
| Average Daily Volume | 11,065,000 |
MRK
VS S&P 500 (SPY)
How do you think MRK will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MRK Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
MRK News and Commentary
- 3 Stocks Springing Back – The Motley Fool
- 3 China Profit Plays – The Motley Fool
- T.V ads for drugs don't work,study finds – Blog at The Motley Fool
- A Big Upgrade for Amylin Pharmaceuticals – The Motley Fool
- Still Enjoying Those Acquisitions, Pfizer? – The Motley Fool
- US sees rise in secondary infections after flu – Reuters
- A Schizophrenic Move by Merck? – The Motley Fool
- What am I missing with MRK? – Blog at The Motley Fool
- Big Pharma/Insurance Bonazza (Scam) – Blog at The Motley Fool
- The World's Best Dividend Stocks – The Motley Fool
- Companies You Should Buy Right Now – The Motley Fool
- UPDATE 1-Merck board approves $3 bln share repurchase – Reuters
- UPDATE:Merck Cholesterol Drug Prescriptions Dropped Last Week – SmartMoney
- Prescriptions For Merck Cholesterol Drugs Dropped Last Week – SmartMoney
- Focus Fuels a Comeback – The Motley Fool
- UPDATE:Judge Dismisses Second Bellwether Case Involving Fosamax – SmartMoney
- Heads Of Wall Street Companies Serve On US-India Forum – SmartMoney
- The Side Effect of Developing Obesity Drugs – The Motley Fool
- Vioxx risks could have been detected earlier-study – Reuters
- The S&P 500's Biggest Movers – The Motley Fool
RSS Headlines
Fool UK
